AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$TWST

Twist Bioscience: Fiscal Q4 Earnings Snapshot

Twist Bioscience Corp. (TWST) reported a Q4 loss of $20.6M, or 32 cents per share, with revenue of $126.6M, exceeding estimates. Annual loss was $130.2M, or $2.08 per share, on revenue of $459.4M. The company forecasts Q1 revenue of $130M-$132M and full-year revenue of $550M-$560M.

Original reporting
finance.yahoo.com
Published Nov 12, 2026, 1:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Twist Bioscience: Fiscal Q4 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TWSTBearishMed
01

Why it matters

The earnings miss may trigger short‑term price declines, but revenue beat and guidance could attract value‑oriented investors.

02

Market read

First report of Q4 results; material for traders tracking biotech small caps.

03

What to watch

Potential cost reductions or upcoming contract wins not disclosed may mitigate the loss impact.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Twist Bioscience provides synthetic DNA for biotech research and development.

Company-level read

Ticker impact

$TWSTBearishHigh confidence
Context

Twist Bioscience reported Q4 loss of $20.6M and revenue beat expectations, with guidance for Q4 revenue $130M-$132M.

Expected impact

likely downside as market prices in the loss, though revenue beat could limit the drop

Evidence & confidence

Loss per share of $0.32 versus expectations, combined with a modest revenue beat, typically triggers a sell-off in small‑cap biotech.

Market effects

Sector

Synthetic DNA market may see short‑term caution, but revenue beat suggests demand resilience.

Regional

Limited to U.S. biotech investors; no broader market effect.

Global

Low global impact beyond niche biotech sector.

Counterpoint

What could challenge this read

Revenue guidance could support a bounce if investors focus on top‑line growth over the loss.

Key entities

  • Company
    Twist Bioscience Corp.

    Synthetic DNA manufacturer.

Read at source← All news

StoryTwist Bioscience reports Q4 earnings beat and raises FY2027 revenue outlook

Also covered by

3 outlets

Related articles

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience (TWST) stock fell 7.1% in pre-market trading after reporting a wider-than-expected Q4 2026 loss of $0.44 per share, despite revenue slightly above estimates at $124.8 million. Analysts had anticipated a loss of $0.38 per share on revenue of $123.6 million. The miss, combined with a bearish report, high short interest, and a declining market, contributed to the decline. The NASDAQ and S&P 500 also fell 0.9% and 0.4%, respectively.

investing.com
$TWSTMed

Twist Bioscience Reports 22% Fiscal 2026 Revenue Growth to $459.4 Million

Twist Bioscience reported fiscal 2026 revenue of $459.4 million, up 22% YoY, and Q4 revenue of $126.6 million, up 28%. Gross margin improved to 52.4%, and adjusted EBITDA reached $2.2 million in Q4. The company forecast fiscal 2027 revenue of $550M-$560M. Twist shipped products to 4,100 customers and 1.3M genes in fiscal 2026, expanding its portfolio with new services and products.

tradingview.com